Barclays
CRVO icon

Barclays’s CervoMed CRVO Stock Holding History

Barclays’s Portfolio CRVO Stock Details CRVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$8 – 5113
2025
Q4 		$8 Hold
1
– – ﹤0.01% 5158
2025
Q3 		$8 Sell
1
-416
-100% -$3.57K ﹤0.01% 5404
2025
Q2 		$2.62K Sell
417
-5,464
-93% -$46.6K ﹤0.01% 5021
2025
Q1 		$53.8K Sell
5,881
-2,676
-31% -$10.2K ﹤0.01% 4595
2024
Q4 		$20K Buy
8,557
+809
+10% +$7.87K ﹤0.01% 4926
2024
Q3 		$113K Buy
7,748
+5,919
+324% +$91.7K ﹤0.01% 4537
2024
Q2 		$31.3K Buy
+1,829
New +$40K ﹤0.01% 4353
2021
Q2 		– Sell
-8
Closed -$1K – 4897
2021
Q1 		$1K Buy
+8
New +$672 ﹤0.01% 4585
2020
Q2 		– Sell
-5
Closed – – 5661
2020
Q1 		$0 Sell
5
-2,041
-100% -$61.9K ﹤0.01% 6182
2019
Q4 		$71K Buy
+2,046
New +$125K ﹤0.01% 5628

Other funds holding CRVO

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
CFG
Citizens Financial Group Providence, Rhode Island $7.19B AUM 23.93% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Barclays's CRVO Position: Q1 2026 in Review

Barclays sold out of CervoMed (CRVO) in Q1 2026, closing a stake of 1 share — an estimated $8 sold.

Barclays first reported a position in CRVO in Q4 2019 and held it in 10 quarters. The position peaked at $113K in Q3 2024. 36 funds tracked by Wall St. Rank hold CRVO as of Q1 2026.

  • Barclays reported no remaining CervoMed position as of Q1 2026 after selling out during the quarter.
  • Barclays sold 1 CervoMed share in Q1 2026, an estimated $8.
  • Barclays first reported a position in CervoMed in Q4 2019 and held it in 10 quarters.
  • Barclays's CervoMed position peaked at $113K in Q3 2024.
  • 36 funds tracked by Wall St. Rank held CervoMed as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.